Molecular and Mathematical Models in Parkinson’s and Alzheimer’s Diseases: Optimizing the Timing of Drugs

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 109

فایل این مقاله در 16 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_CHM-8-8_002

تاریخ نمایه سازی: 27 شهریور 1403

چکیده مقاله:

Circadian rhythms, which regulate various physiological processes, play a significant role in neurodegenerative diseases. This study utilized a detailed mathematical modeling approach to optimize the timing of drug administration for Alzheimer's and Parkinson's medications. The term "optimize the timing of drug administration" refers to the process of determining the most effective dosing schedules based on circadian rhythms. Optimization was defined by aligning drug administration times with the body's natural circadian rhythms to maximize therapeutic efficacy and minimize side effects. Criteria for "optimal dosing schedules" included achieving peak drug concentrations during key periods of circadian protein activity and aligning dosing times with the body’s biological clock. The models integrated pharmacokinetic and pharmacodynamic data with the dynamic interactions of core circadian clock proteins (BMAL۱/CLOCK and PER/CRY) through ordinary differential equations (ODEs). These equations simulated the concentration of these proteins and drugs over time, allowing for the prediction of optimal dosing schedules that align with the body's natural circadian rhythms. The addition of melatonin demonstrated potential benefits. AutoDock Vina and GROMACS software were used for molecular docking simulations. For Alzheimer's disease, simulations identified that Donepezil achieves maximum efficacy when administered at midnight, Memantine in the morning, and Rivastigmine at noon. In Parkinson's disease, Levodopa was most effective when administered in the morning, Pramipexole at noon, and Rasagiline in the evening. Combining these drugs with melatonin resulted in further stabilization of circadian protein levels and extended the therapeutic effects of the drugs. Binding energies for all drug molecules were lower than for melatonin in each clock protein complex, indicating that melatonin could enhance therapy. These findings provide a strong basis for future clinical studies to validate time-optimized pharmacotherapy as a strategy to improve the management of Alzheimer's and Parkinson's diseases.

نویسندگان

Emine Erdag

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Near East University, Nicosia, Cyprus

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • . Leng Y., Musiek E.S., Hu K., Cappuccio F.P.,Yaffe K., ...
  • . Chen Y.-C., Wang W.-S., Lewis S.J.,Wu S.-L., Journal of ...
  • . Partch C.L., Green C.B.,Takahashi J.S., Molecular architecture of the ...
  • . Potter G.D., Skene D.J., Arendt J., Cade J.E., Grant ...
  • . Murugan A., Husain K., Rust M.J., Hepler C., Bass ...
  • . Fagiani F., Di Marino D., Romagnoli A., Travelli C., ...
  • . Ye R., Selby C.P., Chiou Y.-Y., Ozkan-Dagliyan I., Gaddameedhi ...
  • . Cao X., Wang L., Selby C.P., Lindsey-Boltz L.A.,Sancar A., ...
  • . Hunt J., Coulson E.J., Rajnarayanan R., Oster H., Videnovic ...
  • . Korshunov K.S., Blakemore L.J.,Trombley P.Q., Dopamine: A modulator of ...
  • . Musiek E.S.,Holtzman D.M., Mechanisms linking circadian clocks, sleep, and ...
  • . Zeng Y., Guo Z., Wu M., Chen F.,Chen L., ...
  • . Leloup J.-C.,Goldbeter A., Toward a detailed computational model for ...
  • . Tyson J.J., Hong C.I., Thron C.D.,Novak B., A simple ...
  • . Forger D.B.,Peskin C.S., A detailed predictive model of the ...
  • . Warfield A.E., Gupta P., Ruhmann M.M., Jeffs Q.L., Guidone ...
  • . Mattis J.,Sehgal A., Circadian rhythms, sleep, and disorders of ...
  • . Ahmad F., Sachdeva P., Sarkar J.,Izhaar R., Circadian dysfunction ...
  • . Hirsch E.C., Jenner P.,Przedborski S., Pathogenesis of parkinson's disease, ...
  • . Kandiah N., Pai M.-C., Senanarong V., Looi I., Ampil ...
  • . Zisapel N., New perspectives on the role of melatonin ...
  • . Nayak L.,Henchcliffe C., Rasagiline in treatment of parkinson’s disease, ...
  • . Truong V.T., Baverel P.G., Lythe G.D., Vicini P., Yates ...
  • . Asgari‐Targhi A.,Klerman E.B., Mathematical modeling of circadian rhythms, Wiley ...
  • . Fuhr L., Abreu M., Pett P.,Relógio A., Circadian systems ...
  • . for Nursing O.R., Ernstmeyer K., Christman E., Antimicrobials. In ...
  • . Daryaee F.,Tonge P.J., Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding ...
  • . Wang L., Soon G.H., Seng K.-Y., Li J., Lee ...
  • . Rathor P.,Ch R., Metabolic basis of circadian dysfunction in ...
  • . Kim J., Jang S., Choe H.K., Chung S., Son ...
  • . Tan Y.-Y., Jenner P.,Chen S.-D., Monoamine oxidase-b inhibitors for ...
  • . Grossberg G.T., Cholinesterase inhibitors for the treatment of alzheimer's ...
  • . Liu C.,Gillette M.U., Cholinergic regulation of the suprachiasmatic nucleus ...
  • . Kandiah N., Pai M.-C., Senanarong V., Looi I., Ampil ...
  • . Liu J., Chang L., Song Y., Li H.,Wu Y., ...
  • . Forli S., Huey R., Pique M.E., Sanner M.F., Goodsell ...
  • . Al-Karmalawy A.A., Dahab M.A., Metwaly A.M., Elhady S.S., Elkaeed ...
  • . Kumari R., Kumar R., Consortium O.S.D.D.,Lynn A., G_mmpbsa a ...
  • . Haskologlu I.C., Erdag E., Sehirli A.O., Uludag O.,Abacioglu N., ...
  • . Zhang W., Xiong Y., Tao R., Panayi A.C., Mi ...
  • . Bush W.S.,Siegelmann H.T., Circadian synchrony in networks of protein ...
  • . Gabryelska A., Turkiewicz S., Karuga F.F., Sochal M., Strzelecki ...
  • . Hirsch L., Jette N., Frolkis A., Steeves T.,Pringsheim T., ...
  • . Videnovic A.,Golombek D., Circadian dysregulation in parkinson's disease, Neurobiology ...
  • . Videnovic A.,Golombek D., Circadian and sleep disorders in parkinson's ...
  • . Obeso J., Rodriguez-Oroz M., Marin C., Alonso F., Zamarbide ...
  • . Turnbull K.,Murphy K., Importance of timely administration of dopaminergic ...
  • . Yahalom G., Cohen O.S., Warmann-Alaluf N., Shabat C., Strauss ...
  • . Dowling G.A., Mastick J., Colling E., Carter J.H., Singer ...
  • . Diederich N.J., Vaillant M., Mancuso G., Lyen P.,Tiete J., ...
  • . Korshunov K.S., Blakemore L.J.,Trombley P.Q., Dopamine: A modulator of ...
  • . Kesner A.J.,Lovinger D.M., Wake up and smell the dopamine: ...
  • . Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic ...
  • . Ko C.H.,Takahashi J.S., Molecular components of the mammalian circadian ...
  • . Hirayama J., Cho S.,Sassone-Corsi P., Circadian control by the ...
  • . Musiek E.S.,Holtzman D.M., Mechanisms linking circadian clocks, sleep, and ...
  • . Kazui H., Adachi H., Kanemoto H., Yoshiyama K., Wada ...
  • . dos Santos Moraes W.A., Poyares D.R., Guilleminault C., Ramos ...
  • . Grossberg G.T., Cholinesterase inhibitors for the treatment of alzheimer's ...
  • . Hut R.,Van der Zee E., The cholinergic system, circadian ...
  • . McMartin L., Kiraly M., Heller H.C., Madison D.V.,Ruby N.F., ...
  • . Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti ...
  • . Ahmad F., Sachdeva P., Sarkar J.,Izhaar R., Circadian dysfunction ...
  • . Kutzing M.K., Luo V.,Firestein B.L., Protection from glutamate-induced excitotoxicity ...
  • . Ma H., Yan J., Sun W., Jiang M.,Zhang Y., ...
  • . Alghamdi B., The neuroprotective role of melatonin in neurological ...
  • نمایش کامل مراجع